PPARγ LBD (human recombinant)

Product Description

Stability : 6 months
Formulation :
A solution in 50 mM sodium phosphate, pH 7.2, containing 20% glycerol, 150 mM sodium chloride, and 1 mM DTT
Description :
Structurally, PPARγ can be described by two primary domains - a ligand binding domain (LBD) and a DNA binding domain (DBD). Binding of activating ligands to the LBD promotes heterodimerization with retinoic acid-like receptor (RXR) resulting in the regulated expression of target genes, a significant number of which are related to lipid metabolism. Select members of the thiazolidinedione class of PPARγ ligands, which includes rosiglitazone and pioglitazone, are currently used for the treatment of insulin resistance associated with type II diabetes.
Purity : >90%
Storage : -80°C

Disclaimer: the information on this website is from the internet for reference only. Please refer to the actual instructions attached to the product and the final interpretation is owned by the company.

Send inquiry online For more product information and prices

(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)

After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone Swiss

Email: sales@raw-pharmaceutical-materials.com
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: